Leading with science – together.
Our mission is to extend access to life-saving treatments through science and care. In this
goal, we are joined by healthcare and biotechnology professionals who trust in our
biopharmaceuticals, collaborators who share our passion, and most importantly, patients
– whose needs remain at the heart of everything we do.
Our Areas of Science
Our portfolio over the last 25 years demonstrates our expertise in developing, manufacturing, and distributing biopharmaceuticals and catering to patients' unmet needs. This is all made possible by the passion, empathy and dynamism of our people.
With seven commercially available and internationally marketed products, and over 10
products in the pipeline, we demonstrate our care through scientific advancements.
We are now venturing into the transformative space of CGT, building a facility dedicated to
advancing CAR-T cell therapies.
Dr. Reddy’s Heritage
Driven by the purpose of GOOD HEALTH CAN’T WAIT we are your trusted partner. Since
1984, Dr. Reddy’s has established a global presence that has improved the lives of over
half a billion patients.
Our Products
Our labs, our scientists, and our research – we are all rooting for a healthier world. Each biosimilar product is a testament to our belief in accessibility for all. We are invested in product innovation in the industry and believe that the best biotech companies are ones that are always thinking ahead.
Our Commitments
Empathy at the core of any business leads to solutions shaped for life. Read about our goals, policies, and initiatives to see how we care for our community, our planet, and our people.
Our People
Our commitment to Diversity, Equity, and Inclusion (DEI) is central to our mission to serve patients effectively. We believe our workforce's diversity should reflect the communities we serve, enabling us to understand their needs and deliver the best healthcare solutions.
Our Network
- Publication
- 06-12-2019
Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma
- Publication
- 04-11-2022
Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamics evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
- Publication
- 31-12-2017
Comparative double-blind randomized trial of 2 rituximab products in patients with CD20+ diffuse large B-cell lymphoma (DLBCL), at Chicago, IL,
- Publication
- 02-12-2016
Comparison of Pharmacokinetics and Pharmacodynamics of Two Anti-CD20 Monoclonal Antibodies (Candidate Biosimilar DRL-Rituximab and Innovator Reference Product Rituximab (Mabthera) in a Randomised, Multi-Centre, Double-Blind, Parallel Group Study of CHOP with Rituximab Chemotherapy in Patients with CD20-Positive Diffuse Large B-Cell Lymphoma.
Kiran Koshti
Biologics
Kokku Yaswanth
Quality
Sheela R Meher
Reg. Affairs
Naveen Verma
Manufacturing
Rupkatha
IPM
Bricks of Biologics, appreciates the contribution and celebrates our people who are the building blocks of Dr. Reddy's Biologics.
Bricks of biologics in general refers to bio-bricks as genetic building blocks which are DNA sequences that can be assembled to create complex biological systems.